




Instance: composition-en-52a624241d4cc518b719672757fc515f
InstanceOf: CompositionUvEpi
Title: "Composition for cinacalcet Package Leaflet"
Description:  "Composition for cinacalcet Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpd930151bd8b1d8eacf4d31aba1913fe2)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - cinacalcet"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Cinacalcet Mylan is and what it is used for </li>
<li>What you need to know before you take Cinacalcet Mylan  </li>
<li>How to take Cinacalcet Mylan </li>
<li>Possible side effects </li>
<li>How to store Cinacalcet Mylan  </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What cinacalcet is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What cinacalcet is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Cinacalcet Mylan contains the active ingredient cinacalcet, which works by controlling the levels of 
parathyroid hormone (PTH), calcium and phosphorous in your body. It is used to treat problems with 
organs called parathyroid glands. The parathyroids are four small glands in the neck, near the thyroid 
gland, that produce parathyroid hormone (PTH).  </p>
<p>Cinacalcet Mylan is used in adults:  </p>
<p>to treat secondary hyperparathyroidism in adults with serious kidney disease who need dialysis 
to clear their blood of waste products  </p>
<p>to reduce high levels of calcium in the blood (hypercalcaemia) in adult patients with parathyroid 
cancer  </p>
<p>to reduce high levels of calcium in the blood (hypercalcaemia) in adult patients with primary 
hyperparathyroidism when removal of the parathyroid gland is not possible.  </p>
<p>Cinacalcet Mylan is used in children aged 3 years to less than 18 years of age:  </p>
<p>to treat secondary hyperparathyroidism in patients with serious kidney disease who need 
dialysis to clear their blood of waste products, whose condition is not controlled with other 
treatments. </p>
<p>In primary and secondary hyperparathyroidism too much PTH is produced by the parathyroid glands. 
 Primary  means that the hyperparathyroidism is not caused by any other condition and  secondary<br />
means that the hyperparathyroidism is caused by another condition, e.g. kidney disease. Both primary 
and secondary hyperparathyroidism can cause the loss of calcium in the bones, which can lead to bone 
pain and fractures, problems with blood and heart vessels, kidney stones, mental illness and coma. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take cinacalcet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take cinacalcet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Cinacalcet Mylan  </p>
<p>if you are allergic to cinacalcet or any of the other ingredients of this medicine (listed in section 6). </p>
<p>if you have low levels of calcium in your blood. Your doctor will monitor your blood calcium 
levels. </p>
<p>Warnings and precautions 
Talk to your doctor, pharmacist or nurse before taking Cinacalcet Mylan. 
Before you start taking Cinacalcet Mylan, tell your doctor if you have or have ever had:  </p>
<p>seizures (fits or convulsions). The risk of having seizures is higher if you have had them before;  </p>
<p>liver problems; </p>
<p>heart failure.  </p>
<p>Cinacalcet Mylan reduces calcium levels. Life threatening events and fatal outcomes associated with 
low calcium levels (hypocalcaemia) have been reported in adults and children treated with cinacalcet.  </p>
<p>Please tell your doctor if you experience any of the following which may be signs of low calcium 
levels: spasms, twitches, or cramps in your muscles, or numbness or tingling in your fingers, toes or 
around your mouth or seizures, confusion or loss of consciousness while being treated with Cinacalcet 
Mylan. </p>
<p>Low calcium levels can have an effect on your heart rhythm. Tell your doctor if you experience an 
unusually fast or pounding heartbeat, if you have heart rhythm problems, or if you take medicines 
known to cause heart rhythm problems, while taking Cinacalcet Mylan.  </p>
<p>For additional information see section 4. During treatment with Cinacalcet Mylan, tell your doctor:  </p>
<p>if you start or stop smoking, as this may affect the way Cinacalcet Mylan works.  </p>
<p>Children and adolescents 
Children under the age of 18 with parathyroid cancer or primary hyperparathyroidism must not take 
Cinacalcet Mylan.  </p>
<p>If you are being treated for secondary hyperparathyroidism, your doctor should monitor your calcium 
levels before starting treatment with Cinacalcet Mylan and during treatment with Cinacalcet Mylan. 
You should inform your doctor if you experience any of the signs of low calcium levels as described 
above.   </p>
<p>It is important that you take your dose of Cinacalcet Mylan as advised by your doctor. </p>
<p>Note: 
For children who require doses lower than 30 mg, or who are unable to swallow tablets, other 
strengths/pharmaceutical forms of cinacalcet may be available. </p>
<p>Other medicines and Cinacalcet Mylan<br />
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines 
particularly etelcalcetide or any other medicines that lower the level of calcium in your blood. </p>
<p>You should not take Cinacalcet Mylan together with etelcalcetide. </p>
<p>Tell your doctor if you are taking the following medicines. 
Medicines such as these can affect how Cinacalcet Mylan works: </p>
<p>medicines used to treat skin and fungal infections (ketoconazole, itraconazole and voriconazole) </p>
<p>medicines used to treat bacterial infections (telithromycin, rifampicin and ciprofloxacin)  </p>
<p>a medicine used to treat HIV infection and AIDS (ritonavir)  </p>
<p>a medicine used to treat depression (fluvoxamine).  </p>
<p>Cinacalcet Mylan may affect how medicines such as the following work:  </p>
<p>medicines used to treat depression (amitriptyline, desipramine, nortriptyline and clomipramine) </p>
<p>a medicine used to relieve cough (dextromethorphan) </p>
<p>medicines used to treat changes in heart rate (flecainide and propafenone)  </p>
<p>a medicine used to treat high blood pressure (metoprolol).  </p>
<p>Cinacalcet Mylan with food and drink 
Cinacalcet Mylan should be taken with or shortly after food. </p>
<p>Pregnancy, breast-feeding and fertility 
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask 
your doctor or pharmacist for advice before taking this medicine. </p>
<p>Cinacalcet has not been tested in pregnant women. In case of pregnancy, your doctor may decide to 
modify your treatment, as cinacalcet might harm the unborn baby. </p>
<p>It is not known whether cinacalcet is excreted in human milk. Your doctor will discuss with you if you 
should discontinue either breast-feeding or treatment with Cinacalcet Mylan. </p>
<p>Driving and using machines 
Dizziness and seizures have been reported by patients taking cinacalcet. If you experience these side 
effects do not drive or operate machines. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take cinacalcet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take cinacalcet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor 
or pharmacist if you are unsure. Your doctor will tell you how much Cinacalcet Mylan you must take.  </p>
<p>Cinacalcet Mylan must be taken orally, with or shortly after food. The tablets must be taken whole and 
are not to be chewed, crushed or divided.  </p>
<p>Your doctor will take regular blood samples during treatment to monitor your progress and will adjust 
your dose if necessary.  </p>
<p>If you are being treated for secondary hyperparathyroidism  </p>
<p>The recommended starting dose for Cinacalcet Mylan in adults is 30 mg (one tablet) once per day.  </p>
<p>The recommended starting dose of Cinacalcet Mylan for children aged 3 years to less than 18 years of 
age is no more than 0.20 mg/kg of body weight daily. </p>
<p>If you are being treated for parathyroid cancer or primary hyperparathyroidism  </p>
<p>The recommended starting dose for Cinacalcet Mylan in adults is 30 mg (one tablet) twice per day. </p>
<p>If you take more Cinacalcet Mylan than you should 
If you take more Cinacalcet Mylan than you should you must contact your doctor immediately. 
Possible signs of overdose include numbness or tingling around the mouth, muscle aches or cramps 
and seizures.  </p>
<p>If you forget to take Cinacalcet Mylan 
Do not take a double dose to make up for a forgotten dose.  </p>
<p>If you have forgotten a dose of Cinacalcet Mylan, you should take your next dose as normal.  </p>
<p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>Please tell your doctor immediately: </p>
<p>If you start to get numbness or tingling around the mouth, muscle aches or cramps and seizures. 
These may be signs that your calcium levels are too low (hypocalcaemia). </p>
<p>If you experience swelling of the face, lips, mouth, tongue or throat which may cause difficulty 
in swallowing or breathing (angioedema). </p>
<p>Other possible side effects: </p>
<p>Very common: may affect more than 1 in 10 people </p>
<p>nausea and vomiting, these side effects are normally quite mild and do not last for long. </p>
<p>Common: may affect up to 1 in 10 people </p>
<p>dizziness </p>
<p>numbness or tingling sensation (paraesthesia) </p>
<p>loss (anorexia) or decrease of appetite </p>
<p>muscle pain (myalgia) </p>
<p>weakness (asthenia) </p>
<p>rash </p>
<p>reduced testosterone levels </p>
<p>high potassium levels in the blood (hyperkalaemia) </p>
<p>allergic reactions (hypersensitivity) </p>
<p>headache </p>
<p>seizures (convulsions or fits) </p>
<p>low blood pressure (hypotension) </p>
<p>upper respiratory infection </p>
<p>breathing difficulties (dyspnoea) </p>
<p>cough </p>
<p>indigestion (dyspepsia) </p>
<p>diarrhoea </p>
<p>abdominal pain, abdominal pain - upper </p>
<p>constipation </p>
<p>muscle spasms </p>
<p>back pain </p>
<p>low calcium levels in the blood (hypocalcaemia). </p>
<p>Not known: frequency cannot be estimated from the available data </p>
<p>Hives (urticaria).  </p>
<p>Swelling of the face, lips, mouth, tongue or throat which may cause difficulty in swallowing or 
breathing (angioedema).  </p>
<p>Unusually fast or pounding heart beat which may be associated with low levels of calcium in 
your blood (QT prolongation and ventricular arrhythmia secondary to hypocalcaemia).  </p>
<p>After taking cinacalcet a very small number of patients with heart failure had worsening of their 
condition and/or low blood pressure (hypotension). </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side 
effects not listed in this leaflet. You can also report side effects directly via the national reporting 
system listed in Appendix V. By reporting side effects you can help provide more information on the 
safety of this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store cinacalcet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store cinacalcet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the blister, carton or bottle after EXP. 
The expiry date refers to the last day of that month. </p>
<p>This medicine does not require any special storage conditions. </p>
<p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Cinacalcet Mylan contains 
The active substance is cinacalcet. Each film-coated tablet contains 30 mg, 60 mg or 90 mg of 
cinacalcet (as hydrochloride). </p>
<p>The other ingredients are cellulose, microcrystalline; silica, colloidal anhydrous; povidone; 
crospovidone; magnesium stearate.  </p>
<p>The tablet coating contains hypromellose, titanium dioxide (E171), triacetin, indigo carmine (E132), 
iron oxide yellow (E172). </p>
<p>What Cinacalcet Mylan looks like and contents of the pack </p>
<p>Cinacalcet Mylan 30 mg film-coated tablets are 10.0 mm x 6.4 mm, green, oval, biconvex, bevelled 
edge tablets marked with M on one side of the tablet and CI30 on the other side.   </p>
<p>Cinacalcet Mylan 60 mg film-coated tablets are 12.5 mm x 8.0 mm, green, oval, biconvex, bevelled 
edge tablets marked with M on one side of the tablet and CI60 on the other side.   </p>
<p>Cinacalcet Mylan 90 mg film-coated tablets are 14.3 mm x 9.0 mm, green, oval, biconvex, bevelled 
edge tablets marked with M on one side of the tablet CI90 on the other side.   </p>
<p>Cinacalcet Mylan 30 mg, 60 mg, 90 mg film-coated tablets are available in blister packs of 28 tablets 
and perforated unit dose blister packs of 28 x 1, 30 x 1 and 84 x 1 tablets.  </p>
<p>Cinacalcet Mylan 30 mg film-coated tablets are available in plastic bottles of 100 tablets.  </p>
<p>Not all pack sizes may be marketed. </p>
<p>Marketing Authorisation Holder  </p>
<p>Mylan Pharmaceuticals Limited 
Damastown Industrial Park,<br />
Mulhuddart, Dublin 15,<br />
DUBLIN 
Ireland </p>
<p>Manufacturers 
Mylan Hungary Kft 
H-2900 Kom rom, Mylan utca 1 
Hungary </p>
<p>McDermott Laboratories Limited trading as Gerard Laboratories 
35/36 Baldoyle Industrial Estate, Grange Road, Dublin Ireland </p>
<p>Mylan Germany GmbH 
Zweigniederlassung Bad Homburg v. d. Hoehe, Benzstrasse 1 
Bad Homburg v. d. Hoehe 
Hessen, 61352,<br />
Germany </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder: 
Belgi /Belgique/Belgien 
Mylan bvba/sprl 
T l/Tel: + 32 (0)2 658 61 Lietuva 
Mylan Healthcare UAB 
Tel: + 370 5 205 1   </p>
<p>: +359 2 44 55 Luxembourg/Luxemburg 
Mylan bvba/sprl 
T l/Tel: + 32 (0)2 658 61 (Belgique/Belgien) </p>
<p>esk  republika 
Viatris CZ  s.r.o. 
Tel: + 420 222 004 Magyarorsz g<br />
Mylan EPD Kft. 
Tel.: + 36 1 465 2Danmark 
Viatris ApS<br />
Tlf: +45 28 11 69 Malta 
V.J. Salomone Pharma Ltd 
Tel: + 356 21 22 01 Deutschland 
Viatris Healthcare GmbH 
Tel:  +49 800 0700 Nederland 
Mylan BV 
Tel:  +31 (0)20 426 3Eesti 
BGP Products Switzerland GmbH Eesti filiaal 
Tel: + 372 6363 Norge 
Viatris AS 
Tlf: + 47 66 75 33  <br />
Generics Pharma Hellas <br />
 :  +30 210 993 6 sterreich 
Arcana Arzneimittel GmbH 
Tel: +43 1 416 2Espa a 
Viatris Pharmaceuticals, S.L.U. 
Tel: + 34 900 102 Polska 
Mylan Healthcare Sp. z.o.o. 
Tel.: + 48 22 546 64 France 
Viatris Sant<br />
T l: + 33 4 37 25 75 Portugal 
Mylan, Lda. 
Tel: + 351 214 127 Hrvatska<br />
Viatris Hrvatska d.o.o.<br />
Tel: +385 1 23 50 Ireland 
Mylan Ireland Limited 
Tel: +353 1 8711Rom nia 
BGP Products SRL 
Tel: +40 372 579 Slovenija 
Viatris d.o.o. 
Tel: + 386 1 23 63  sland 
Icepharma hf. 
S mi: +354 540 8Slovensk  republika 
Viatris Slovakia s.r.o. 
Tel: +421 2 32 199 Italia 
Mylan Italia S.r.l. 
Tel: + 39 02 612 46Suomi/Finland 
Viatris Oy 
Puh/Tel: +358 20 720 9 <br />
Varnavas Hadjipanayis Ltd <br />
 : +357 2220 7Sverige 
Viatris AB 
Tel: + 46 (0)8 630 19 Latvija 
Mylan Healthcare SIA 
Tel: +371 676 055 United Kingdom (Northern Ireland) 
Mylan IRE Healthcare Limited 
Tel: +353 18711This leaflet was last revised in  </p>
<p>Other sources of information </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-52a624241d4cc518b719672757fc515f
InstanceOf: CompositionUvEpi
Title: "Composition for cinacalcet Package Leaflet"
Description:  "Composition for cinacalcet Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpd930151bd8b1d8eacf4d31aba1913fe2)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - cinacalcet"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen 
1. Virkning og anvendelse 
2. Det skal du vide, før du begynder at tage Cinacalcet Mylan<br />
3. Sådan skal du tage Cinacalcet Mylan<br />
4. Bivirkninger 
5. Opbevaring 
6. Pakningsstørrelser og yderligere oplysninger </p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What cinacalcet is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What cinacalcet is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Cinacalcet Mylan indeholder det aktive stof cinacalcet, der virker ved at kontrollere niveauerne af 
paratyroideahormon (PTH), calcium og fosfor i kroppen. Det bruges til behandling af sygdomme, der 
skyldes problemer med organer kaldet biskjoldbruskkirtlerne. Biskjoldbruskkirtlerne er fire små kirtler i 
halsen, tæt ved skjoldbruskkirtlen, som producerer paratyroideahormon (PTH). </p>
<p>Cinacalcet Mylan bruges til voksne til: </p>
<ul>
<li>
<p>at behandle sekundær hyperparatyroidisme hos voksne med alvorlig nyresygdom, som har behov 
for dialyse for at fjerne affaldsprodukter fra blodet. </p>
</li>
<li>
<p>at reducere forhøjede calciumniveauer i blodet (hyperkalcæmi) hos voksne patienter med 
biskjoldbruskkirtelkræft. </p>
</li>
<li>
<p>at reducere forhøjede calciumniveauer i blodet (hyperkalcæmi) hos voksne patienter med primær 
hyperparatyroidisme, hos patienter, hvor det ikke er muligt at fjerne biskjoldbruskkirtlen. </p>
</li>
</ul>
<p>Cinacalcet Mylan bruges til børn fra 3 år og op til 18 år til: </p>
<ul>
<li>at behandle sekundær hyperparatyroidisme hos patienter med alvorlig nyresygdom, som har behov 
for dialyse for at fjerne affaldsprodukter fra blodet, og hvis sygdom ikke kan kontrolleres med 
andre behandlinger. </li>
</ul>
<p>Ved primær og sekundær hyperparatyroidisme afgiver biskjoldbruskkirtlerne for meget PTH. “Primær" 
betyder, at hyperparatyroidismen ikke skyldes nogen anden tilstand, og “sekundær" betyder, at 
hyperparatyroidismen skyldes en anden tilstand, for eksempel nyresygdom. Både primær og sekundær 
hyperparatyroidisme kan medføre et for lavt calciumniveau i knoglerne, som kan give smerter i 
knoglerne, knoglebrud, hjerte-kar-sygdom, nyresten, psykiske lidelser og koma. </p>
<p>6 </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take cinacalcet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take cinacalcet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Cinacalcet Mylan  </p>
<ul>
<li>
<p>hvis du er allergisk over for cinacalcet eller et af de øvrige indholdsstoffer (angivet i punkt 6). </p>
</li>
<li>
<p>hvis du har lave calciumniveauer i blodet. Din læge vil kontrollere dine calciumniveauer i 
blodet. </p>
</li>
</ul>
<p>Advarsler og forsigtighedsregler 
Kontakt lægen, apotekspersonalet eller sygeplejersken, før du tager Cinacalcet Mylan. </p>
<p>Tal med din læge, før du begynder at tage Cinacalcet Mylan, hvis du lider eller nogen sinde har lidt af: </p>
<ul>
<li>
<p>krampeanfald (anfald eller kramper). Risikoen for at få krampeanfald er større, hvis du tidligere har 
haft krampeanfald, </p>
</li>
<li>
<p>leversygdom, </p>
</li>
<li>
<p>hjertesvigt. </p>
</li>
</ul>
<p>Cinacalcet Mylan nedsætter calciumniveauerne. Der er indberettet livstruende hændelser og dødeligt 
udfald i forbindelse med lave calciumniveauer (hypokalcæmi) hos voksne og børn, der blev behandlet 
med cinacalcet. </p>
<p>Fortæl det til din læge, hvis du oplever en eller flere af disse tilstande, som kan være tegn på lave 
calciumniveauer: spasmer, muskelspjæt eller muskelkramper, følelsesløshed eller prikken i fingre, 
tæer eller omkring munden, kramper, forvirring eller bevidstløshed, mens du er i behandling med 
Cinacalcet Mylan. </p>
<p>Lave calciumniveauer kan påvirke din hjerterytme. Fortæl det til din læge, hvis du får unormalt hurtige 
eller bankende hjerteslag, hvis du får hjerterytmeproblemer, eller hvis du tager medicin, der vides at 
forårsage hjerterytmeproblemer, mens du tager Cinacalcet Mylan. </p>
<p>Punkt 4 nedenfor indeholder mere information. </p>
<p>Tal med din læge undervejs i behandlingen med Cinacalcet Mylan: </p>
<ul>
<li>hvis du begynder eller holder op med at ryge, da det kan ændre virkningen af Cinacalcet Mylan. </li>
</ul>
<p>Børn og unge 
Børn og unge under 18 år med biskjoldbruskkirtelkræft eller primær hyperparatyroidisme må ikke få 
Cinacalcet Mylan.  </p>
<p>Hvis De behandles for sekundær hyperparatyroidisme, skal Deres læge kontrollere Deres 
calciumniveauer, inden behandlingen med Cinacalcet Mylan starter og under behandlingen med 
Cinacalcet Mylan. De skal fortælle det til Deres læge, hvis De får et eller flere af de tegn på lave 
calciumniveauer, der beskrives ovenfor. </p>
<p>Det er vigtigt, at De tager deres Cinacalcet Mylan-dosis efter lægens anvisninger. </p>
<p>Bemærk: 
Til børn, der har brug for lavere doser end 30 mg, eller som ikke kan synke tabletter, kan der være andre 
styrker/lægemiddelformuleringer af cinacalcet produkter tilgængelige. </p>
<p>Brug af anden medicin sammen med Cinacalcet Mylan 
Fortæl det altid til lægen eller apotekspersonalet, hvis De bruger anden medicin, for nylig har brugt anden 
medicin eller planlægger at bruge anden medicin. Det gælder især etelcalcetid eller anden medicin, der 
sænker niveauet af calcium i blodet. </p>
<p>Du må ikke få Cinacalcet Mylan samtidig med etelcalcetid. </p>
<p>7 </p>
<p>Fortæl det til din læge, hvis du tager en eller flere af følgende lægemidler. </p>
<p>Nedenstående medicin kan have betydning for, hvordan Cinacalcet Mylanvirker: </p>
<ul>
<li>
<p>medicin, som anvendes til behandling af hud- og svampeinfektioner (ketoconazol, itraconazol og 
voriconazol), </p>
</li>
<li>
<p>medicin, som anvendes til behandling af bakterieinfektioner (telithromycin, rifampicin og 
ciprofloxacin), </p>
</li>
<li>
<p>medicin, som anvendes til behandling af hiv og aids (ritonavir), </p>
</li>
<li>
<p>medicin, der anvendes til behandling af depression (fluvoxamin). </p>
</li>
</ul>
<p>Cinacalcet Mylankan have betydning for, hvordan følgende medicin virker: </p>
<ul>
<li>
<p>medicin, som anvendes til behandling af depression (amitriptylin, desipramin, nortriptylin og 
clomipramin), </p>
</li>
<li>
<p>medicin, som anvendes til at lindre hoste (dextromethorphan), </p>
</li>
<li>
<p>medicin, som anvendes til behandling af hjerterytmeforstyrrelser (flecainid og propafenon), </p>
</li>
<li>
<p>medicin, som anvendes til behandling af forhøjet blodtryk (metoprolol). </p>
</li>
</ul>
<p>Brug af Cinacalcet Mylan sammen med mad og drikke 
Cinacalcet Mylan skal tages sammen med eller kort tid efter indtagelse af mad. </p>
<p>Graviditet, amning og frugtbarhed 
Hvis du er gravid eller ammer, har mistanke om, at du er gravid, eller planlægger at blive gravid, skal du 
spørge din læge eller apotekspersonaletet til råds, før du tager dette lægemiddel. </p>
<p>Cinacalcet er ikke blevet undersøgt på gravide kvinder. Hvis du er gravid, kan lægen beslutte at ændre 
behandlingen, da cinacalcet kan være skadeligt for fostret. </p>
<p>Det vides ikke, om cinacalcet udskilles i mælken hos mennesker. Du og din læge skal afklare, om det er 
bedst at ophøre med amning eller afbryde behandlingen med Cinacalcet Mylan. </p>
<p>Trafik- og arbejdssikkerhed 
Der er indberettet svimmelhed og krampeanfald fra patienter, som fik cinacalcet. Hvis du oplever disse 
bivirkninger må du ikke føre motorkøretøj eller betjene maskiner. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take cinacalcet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take cinacalcet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens eller apotekspersonalets anvisning. Er du i tvivl, så spørg 
lægen eller apotekspersonalet. Din læge vil fortælle dig, hvor meget Cinacalcet Mylan du skal tage. </p>
<p>Cinacalcet Mylan skal indtages gennem munden sammen med eller kort tid efter indtagelse af mad. 
Tabletterne skal tages hele og må ikke tygges, knuses eller deles. </p>
<p>Din læge vil tage regelmæssige blodprøver under behandlingen for at følge udviklingen og justere dosis 
efter behov. </p>
<p>Hvis du er under behandling for sekundær hyperparatyroidisme </p>
<p>Den normale startdosis af Cinacalcet Mylan for voksne er 30 mg (én tablet) én gang dagligt. </p>
<p>Den normale startdosis af Cinacalcet Mylan for børn i alderen 3 år og op til 18 år er maksimalt 0,mg/kg legemsvægt dagligt. </p>
<p>Hvis du er under behandling for biskjoldbruskkirtelkræft eller primær hyperparatyroidisme </p>
<p>Den normale startdosis af Cinacalcet Mylan for voksne er 30 mg (én tablet) to gange dagligt. </p>
<p>8 </p>
<p>Hvis du har taget for meget Cinacalcet Mylan 
Hvis du har taget for meget Cinacalcet Mylan, skal du straks kontakte din læge. Tegn på en overdosis kan 
omfatte følelsesløshed eller en prikken omkring munden, muskelsmerter eller -kramper samt 
krampeanfald. </p>
<p>Hvis du har glemt at tage Cinacalcet Mylan 
Du må ikke tage en dobbeltdosis som erstatning for den glemte tablet. </p>
<p>Hvis du har glemt at tage en dosis Cinacalcet Mylan, skal du tage den næste dosis som normalt. </p>
<p>Spørg lægen, apotekspersonalet eller sygeplejersken, hvis der er noget, du er i tvivl om. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. </p>
<p>Fortæl det straks til lægen: </p>
<ul>
<li>hvis du begynder at få følelsesløshed eller en prikken omkring munden, muskelsmerter eller -
kramper eller krampeanfald. Dette kan være tegn på, at dine calciumniveauer er for lave 
(hypokalcæmi) 
• hvis du får hævelse i ansigt, læber, mund, tunge eller hals, som kan give synke- eller 
åndedrætsbesvær (angioødem). </li>
</ul>
<p>Andre mulige bivirkninger: </p>
<p>Meget almindelige (kan forekomme hos  flere end 1 ud af 10 personer): </p>
<ul>
<li>kvalme og opkastning. Disse bivirkninger er normalt ret milde og er ikke vedvarende. </li>
</ul>
<p>Almindelige (kan forekomme hos op til 1 ud af 10 personer): </p>
<ul>
<li>
<p>svimmelhed </p>
</li>
<li>
<p>følelsesløshed eller prikkende fornemmelse (paræstesi) </p>
</li>
<li>
<p>appetitløshed eller nedsat appetit </p>
</li>
<li>
<p>muskelsmerter (myalgi) </p>
</li>
<li>
<p>udmattethed (asteni) </p>
</li>
<li>
<p>udslæt </p>
</li>
<li>
<p>reducerede testosteronniveauer </p>
</li>
<li>
<p>høje kaliumniveauer i blodet (hyperkaliæmi) </p>
</li>
<li>
<p>allergiske reaktioner (overfølsomhed) </p>
</li>
<li>
<p>hovedpine </p>
</li>
<li>
<p>kramper eller krampeanfald </p>
</li>
<li>
<p>lavt blodtryk </p>
</li>
<li>
<p>infektion i øvre luftveje </p>
</li>
<li>
<p>vejrtrækningsbesvær (dyspnø) </p>
</li>
<li>
<p>hoste </p>
</li>
<li>
<p>fordøjelsesbesvær (dyspepsi) </p>
</li>
<li>
<p>diarré </p>
</li>
<li>
<p>mavesmerter - smerter i den øvre del af maven </p>
</li>
<li>
<p>forstoppelse </p>
</li>
<li>
<p>muskelspasmer </p>
</li>
<li>
<p>rygsmerter </p>
</li>
<li>
<p>lave calciumniveauer i blodet (hypokalcæmi). </p>
</li>
</ul>
<p>Ikke kendt (hyppigheden kan ikke vurderes ud fra tilgængelige data): </p>
<ul>
<li>
<p>nældefeber (urticaria) </p>
</li>
<li>
<p>hævelse i ansigt, læber, mund, tunge eller hals, som kan give synke- eller åndedrætsbesvær 
(angioødem) </p>
</li>
</ul>
<p>9 </p>
<ul>
<li>unormalt hurtige eller bankende hjerteslag, der kan være forbundet med lave niveauer af calcium i 
dit blod (QT-forlængelse og ventrikulær arytmi sekundært til hypokalcæmi). </li>
</ul>
<p>I meget få tilfælde hos patienter med hjertesvigt blev dette forværret efter indtagelse af cinacalcet, 
og/eller patienterne fik lavt blodtryk (hypotension). </p>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge, apotekspersonalet eller sygeplejersken. Dette 
gælder også mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende 
kan også indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem 
anført i Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere 
information om sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store cinacalcet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store cinacalcet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på pakningen og blisterkortet efter EXP. 
Udløbsdatoen er den sidste dag i den nævnte måned. </p>
<p>Dette lægemiddel kræver ingen særlige forholdsregler vedrørende opbevaring. </p>
<p>Spørg apotekspersonalet, hvordan du skal bortskaffe medicinrester. Af hensyn til miljøet må du ikke 
smide medicinrester i afløbet, toilettet eller skraldespanden. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Cinacalcet Mylan indeholder 
Aktivt stof: cinacalcet. Hver filmovertrukket tablet indeholder 30 mg, 60 mg eller 90 mg cinacalcet (som 
hydroklorid). </p>
<p>Øvrige indholdsstoffer er cellulose, mikrokrystallinsk cellulose, silica, vandfri kolloid, povidone, 
crospovidon, magnesiumstearat. </p>
<p>Tabletterne er overtrukket med hypromellose, titandioxid (E171), triacetin, indigotin (E132), gul jernoxid 
(E172). </p>
<p>Udseende og pakningsstørrelser </p>
<p>Cinacalcet Mylan 30 mg filmovertrukne tabletter er 10,0 mm x 6,4 mm, grønne, ovale, bikonvekse 
tabletter med afslebne kanter markeret på den ene side med M og på den anden side med CI30. Cinacalcet Mylan 60 mg filmovertrukne tabletter er 12,5 mm x 8,0 mm, grønne, ovale, bikonvekse 
tabletter med afslebne kanter markeret på den ene side med M og på den anden side med CI60. Cinacalcet Mylan 90 mg filmovertrukne tabletter er 14,3 mm x 9,0 mm, grønne, ovale, bikonvekse 
tabletter med afslebne kanter markeret på den ene side med M og på den anden side med CI90. Cinacalcet Mylan 30 mg, 60 mg, 90 mg filmovertrukne tabletter fås i blisterpakninger med 28 tabletter og 
perforerede blisterpakninger med enhedsdoseringer med 28 x 1, 30 x 1 og 84 x 1 tabletter. </p>
<p>Cinacalcet Mylan 30 mg filmovertrukne tabletter fås i plastikbeholdere med 100 tabletter. </p>
<p>Ikke alle pakningsstørrelser er nødvendigvis markedsført. </p>
<p>Indehaver af markedsføringstilladelsen 
Mylan Pharmaceuticals Limited 
Damastown Industrial Park,<br />
Mulhuddart, Dublin 15,<br />
DUBLIN 
Irland </p>
<p>Fremstiller 
Mylan Hungary Kft 
H-2900 Komárom, Mylan utca 1 
Ungarn </p>
<p>McDermott Laboratories Limited trading as Gerard Laboratories 
35/36 Baldoyle Industrial Estate, Grange Road, Dublin Irland </p>
<p>Mylan Germany GmbH 
Zweigniederlassung Bad Homburg v. d. Hoehe, Benzstrasse 1 
Bad Homburg v. d. Hoehe 
Hessen, 61352, 
Tyskland </p>
<p>Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du henvende dig til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen. </p>
<p>België/Belgique/Belgien 
Viatris 
Tél/Tel: + 32 (0)2 658 61 Lietuva 
Viatris UAB 
Tel: + 370 5 205 1 
България<br />
Майлан ЕООД 
Тел: +359 2 44 55<br />
Luxembourg/Luxemburg 
Viatris 
Tél/Tel: + 32 (0)2 658 61 (Belgique/Belgien) </p>
<p>Česká republika 
Viatris CZ s.r.o. 
Tel: + 420 222 004 Magyarország<br />
Viatris Healthcare Kft. 
Tel.: + 36 1 465 2 
Danmark 
Viatris ApS<br />
Tlf: +45 28 11 69<br />
Malta 
V.J. Salomone Pharma Ltd 
Tel: + 356 21 22 01<br />
Deutschland 
Viatris Healthcare GmbH 
Tel:  +49 800 0700 Nederland 
Mylan BV 
Tel:  +31 (0)20 426 3 
Eesti 
Viatris OÜ 
Tel: + 372 6363<br />
Norge 
Viatris AS 
Tlf: + 47 66 75 33<br />
Ελλάδα<br />
Viatris Hellas Ltd 
Τηλ:  +30 2100 100 002  </p>
<p>Österreich 
Viatris Austria GmbH 
Tel: +43 1 86 </p>
<p>España 
Viatris Pharmaceuticals, S.L. 
Tel: + 34 900 102<br />
Polska 
Viatris Healthcare Sp. z.o.o. 
Tel.: + 48 22 546 64<br />
France 
Viatris Santé 
Tél: + 33 4 37 25 75 Portugal 
Mylan, Lda. 
Tel: + 351 214 127<br />
Hrvatska<br />
Viatris Hrvatska d.o.o.<br />
Tel: +385 1 23 50<br />
Ireland 
Viatris Limited 
Tel: +353 1 8711 
România 
BGP Products SRL 
Tel: +40 372 579<br />
Slovenija 
Viatris d.o.o. 
Tel: + 386 1 23 63<br />
Ísland 
Icepharma hf. 
Sími: +354 540 8000  </p>
<p>Slovenská republika 
Viatris Slovakia s.r.o. 
Tel: +421 2 32 199 Italia 
Viatris Italia S.r.l. 
Tel: + 39 02 612 46 
Suomi/Finland 
Viatris Oy 
Puh/Tel: +358 20 720 9 
Κύπρος<br />
GPA Pharmaceuticals Ltd <br />
Τηλ: +357 22863100  </p>
<p>Sverige 
Viatris AB 
Tel: + 46 (0)8 630 19 00<br />
Latvija 
Viatris SIA 
Tel: +371 676 055<br />
United Kingdom (Northern Ireland) 
Mylan IRE Healthcare Limited 
Tel: +353 18711 </p>
<p>Denne indlægsseddel blev senest ændret </p>
<p>Andre informationskilder </p>
<p>De kan finde yderligere information om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu. </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-52a624241d4cc518b719672757fc515f
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for cinacalcet Package Leaflet for language en"
Description: "ePI document Bundle for cinacalcet Package Leaflet for language en"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-52a624241d4cc518b719672757fc515f"
* entry[0].resource = composition-en-52a624241d4cc518b719672757fc515f

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp52a624241d4cc518b719672757fc515f"
* entry[=].resource = mp52a624241d4cc518b719672757fc515f
                            
                    
Instance: bundlepackageleaflet-da-52a624241d4cc518b719672757fc515f
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for cinacalcet Package Leaflet for language da"
Description: "ePI document Bundle for cinacalcet Package Leaflet for language da"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-52a624241d4cc518b719672757fc515f"
* entry[0].resource = composition-da-52a624241d4cc518b719672757fc515f

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp52a624241d4cc518b719672757fc515f"
* entry[=].resource = mp52a624241d4cc518b719672757fc515f
                            
                    



Instance: mp52a624241d4cc518b719672757fc515f
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product cinacalcet"
Description: "cinacalcet"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/15/1054/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"


* indication = "Secondary hyperparathyroidism"


* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"


* name
  * productName = "cinacalcet"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#DK "DK"
    * jurisdiction = urn:iso:std:iso:3166#DK "DK"
    * language = urn:ietf:bcp:47#en  "en"




RuleSet: 52a624241d4cc518b719672757fc515fListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "cinacalcet"

* status = #current
* mode = #working

* title = "List of all ePIs associated with cinacalcet"

* subject = Reference(mpd930151bd8b1d8eacf4d31aba1913fe2)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#cinacalcet "cinacalcet"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-52a624241d4cc518b719672757fc515f) // cinacalcet en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-52a624241d4cc518b719672757fc515f) // cinacalcet da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-52a624241d4cc518b719672757fc515f
InstanceOf: List

* insert 52a624241d4cc518b719672757fc515fListRuleset
    